Aims/hypothesis Many of the effects of resveratrol are consistent with the activation of AMP-activated protein kinase (AMPK), silent information regulator T1 (SIRT1) and peroxisome proliferator-activated receptor (PPAR)γ co-activator 1α (PGC-1α), which play key roles in the regulation of lipid and glucose homeostasis, and in the control of oxidative stress. We investigated whether resveratrol has protective effects on the kidney in type 2 diabetes. Methods Four groups of male C57BLKS/J db/m and db/db mice were used in this study. Resveratrol was administered via gavage to diabetic and non-diabetic mice, starting at 8 weeks of age, for 12 weeks. Results The db/db mice treated with resveratrol had decreased albuminuria. Resveratrol ameliorated glomerular matrix expansion and inflammation. Resveratrol also lowered the NEFA and triacylglycerol content of the kidney, and this action was related to increases in the phosphorylation of AMPK and the activation of SIRT1-PGC-1α signalling and of the key downstream effectors, the PPARα-oestrogen-related receptor (ERR)-1α-sterol regulatory element-binding protein 1 (SREBP1). Furthermore, resveratrol decreased the activity of phosphatidylinositol-3 kinase (PI3K)-Akt phosphorylation and class O forkhead box (FOXO)3a phosphorylation, which resulted in a decrease in B cell leukaemia/ lymphoma 2 (BCL-2)-associated X protein (BAX) and increases in BCL-2, superoxide dismutase (SOD)1 and SOD2 production. Consequently, resveratrol reversed the increase in renal apoptotic cells and oxidative stress, as reflected by renal 8-hydroxy-deoxyguanosine (8-OH-dG), urinary 8-OH-dG and isoprostane concentrations. Resveratrol prevented high-glucose-induced oxidative stress and apoptosis in cultured mesangial cells through the phosphorylation of AMPK and activation of SIRT1-PGC-1α signalling and the downstream effectors, PPARα-ERR-1α-SREBP1. Conclusions/interpretation The results suggest that resveratrol prevents diabetic nephropathy in db/db mice by the phosphorylation of AMPK and activation of SIRT1-PGC-1α signalling, which appear to prevent lipotoxicity-related apoptosis and oxidative stress in the kidney.
Introduction
Diabetic nephropathy is the most prevalent cause of endstage renal disease in developed countries, including Korea [1] . Despite progress in pharmacological strategies to modulate diabetes, the number of patients entering renal failure remains extremely high and the development of new classes of therapeutic agents is eagerly anticipated. Lipotoxicity is one of the causal factors of the progression of diabetic and obesity-induced renal damage [2] , but the underlying molecular mechanism remains elusive.
Resveratrol is a natural plant polyphenol that may target ageing and obesity-related chronic diseases by preventing inflammation and oxidative stress [3] [4] [5] [6] . Resveratrol activates silent information regulator T1 (SIRT1), an NAD + -dependent protein deacetylase, and AMP-activated protein kinase (AMPK). It subsequently augments peroxisome proliferator-activated receptor (PPAR)γ co-activator 1α (PGC-1α), endothelial nitric oxide synthase (eNOS) and class O forkhead box (FOXO) activation, which is followed by catabolic metabolism, mitochondrial activation, angiogenesis and enhanced cell survival [3] [4] [5] [6] . Some of the bestcharacterised effects of SIRT1 include increased stress resistance and altered metabolism mediated by changes in the activity of the transcriptional factor FOXO [3] , suppression of nuclear factor κ B (NF-κB)-dependent inflammatory responses [4] and the promotion of gluconeogenesis, fatty acid oxidation and mitochondrial biogenesis, through PGC-1α [5, 6] . The activation of SIRT1 by resveratrol is substrate dependent and many of its effects are consistent with the modulation of its target genes [7, 8] . Hepatocyte-specific deletion of Sirt1 impairs PPARα signalling and decreases fatty acid β-oxidation, whereas the overexpression of Sirt1 induces the expression of PPARα targets. SIRT1 interacts with PPARα, and this is required to activate the PPARα coactivator PGC-1α. It has been reported that SIRT1 and PGC-1α form a stable complex and that SIRT1 regulates the activity and acetylation status of PGC-1α [9] . AMPK is a fuel-sensing enzyme that is activated by decreases in the cellular energy state, as reflected by an increased AMP/ATP ratio [10] . When activated, AMPK initiates metabolic and genetic processes that generate ATP (fatty acid oxidation), and inhibits other processes that consume ATP. The former occurs via its effects on various transcriptional activators and co-activators, including PGC-1α and PPARα [11] . The collective results favour the view that SIRT1 and AMPK play a vital role in the regulation of organic lipid homeostasis, and that pharmacological activation of SIRT1 and AMPK may be important for the prevention of obesity-associated metabolic diseases [8, 10, 11] .
Accumulated experimental evidence suggests that PPARα activation attenuates or inhibits several mediators of vascular injury, including lipotoxicty, inflammation, reactive oxygen species (ROS) generation, endothelial dysfunction, angiogenesis and thrombosis in type 2 diabetes and high-fat-diet-induced renal damage [12, 13] , which are all associated with AMPK activation and eNOS production [14] [15] [16] . PPARs activate PGC-1α/β and its key downstream effector oestrogen-related receptor (ERR)-1α, which induces mitochondrial biogenesis and enhanced mitochondrial antioxidative capacity to provide relief from oxidative stress [17, 18] . Additionally, PPARα activation can suppress the sterol regulatory element-binding protein 1 (SREBP1) pathway through the reduction of liver X receptor (LXR)/retinoid X receptor (RXR) formation in the liver, which plays a crucial role in the regulation of fatty acid metabolism [19] . Notably, FOXO3a is a direct transcriptional regulator of a group of oxidative protection genes and this regulation requires PGC-1α. FOXO3A and PGC-1α interact directly and cooperatively and their interaction regulates mitochondrial oxidative stress [20] .
We hypothesised that resveratrol can potentially prevent renal cell apoptosis and oxidative stress, which are the main causes of renal damage in diabetic nephropathy, via activation of AMPK-SIRT1-PGC-1α and the consequent effects on its target molecules PPARα-ERR-1α and the phosphatidylinositol-3 kinase (PI3K)-Akt-FOXO3a pathway.
Methods
Experimental methods Male 6-week-old C57BLKS/J db/m and db/db mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Four groups of male C57BLKS/J db/m and db/db mice were used in this study. Resveratrol (Sigma-Aldrich, St Louis, MO, USA) dissolved with 0.5% carboxymethyl cellulose sodium salt (CMC), 20 mgkg
, was administered via gavage to diabetic mice (db/db Res, n08) and non-diabetic mice (db/m Res, n08) starting at 8 weeks of age, for 12 weeks [21] . The diabetic db/db group (n08) and the non-diabetic db/m control group (n08) received only 0.5% CMC. The mice were placed in individual metabolism cages (Nalgene, Rochester, NY, USA) with access to water and food ad libitum. After 12 weeks of treatment, the systolic BP was determined by the non-invasive tail-cuff system in conscious mice (IITC Life Science, Woodland Hill, CA, USA) after a 5 day accommodation period. At week 20, all animals were anaesthetised by intraperitoneal injection of a mixture of Rompun, 10 mg/kg (Bayer Korea, Ansan, Gyeonggi-Do, Korea) and Zoletil, 30 mg/kg (Virbac, Carros, France). The mice were killed and the kidneys removed. Immediately following removal, each kidney was divided into the cortex and medullar. All our experiments, including western blots, were performed with renal cortex. The kidneys were rapidly dissected and stored in buffered formalin (10%) for subsequent immunohistochemical analyses. Blood was collected from the left ventricle and the plasma was stored at -70°C for subsequent analyses. HbA 1c was determined from the red cell lysates by HPLC (Bio-Rad, Richmond, CA, USA). The total cholesterol and triacylglycerol concentrations were measured by an autoanalyser (Hitachi 917, Tokyo, Japan) using commercial kits (Wako, Osaka, Japan). NEFA levels were measured with a JCA-BM1250 automatic analyser (JEOL, Tokyo, Japan). The experiments were performed in accordance with our institutional animal care guidelines, and all the procedures complied with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 1996) .
Assessment of renal function and the lipid contents At week 20, the animals were housed in metabolism cages (Nalgene) for 24 h to collect urine for subsequent measurements of the albumin concentrations by an immunoassay (Bayer, Elkhart, IN, USA). Plasma and urine creatinine concentrations were measured, using HPLC (Beckman Instruments, Fullerton, CA, USA). The kidney lipids were extracted using the method of Bligh and Dyer with slight modifications, as previously described [22] .
Light microscopy study The mesangial matrix and glomerular tuft areas were quantified for each glomerular cross-section, using sections stained with periodic acid-Schiff's reagent. More than 30 glomeruli, cut through the vascular pole, were counted per kidney and the average was used for analysis. (Table 1) . Kidney weight, blood glucose and HbA 1c , together with the amount of food eaten, were significantly higher for the db/db mice than for the db/m mice (Table 1) . There were no differences in serum creatinine level and systolic BP between the study groups. There was significantly increased albuminuria and creatinine clearance in the db/db mice compared with the db/m and db/m Res mice. Despite the same degree of hyperglycaemia in the db/db Res and db/db mice, resveratrol treatment restored the albuminuria and creatinine clearance to the levels of the db/m and db/m Res mice ( Table 1) .
Effects of resveratrol on renal phenotype, TGF-β1, type IV collagen and F4/80 There were no differences in the fractional mesangial areas between the db/m and db/m Res mice (Fig. 1a) . In contrast, there was a marked (2.6-fold) increase in the mesangial area in the db/db mice compared with the db/m mice (p<0.01). Consistent with the changes of the mesangial fractional area, the levels of the pro-fibrotic growth factor TGF-β1 and associated extracellular matrix type IV collagen and inflammatory cell glomerular infiltration were significantly increased in the db/db mice compared with the db/m and db/m Res mice (Fig. 1a-e) . All of the diabetes-induced renal phenotypic changes and inflammation seen in the db/db mice were reversed by resveratrol treatment. The significantly increased production of type IV collagen in db/db mice was reversed by resveratrol treatment (ESM Fig. 1 
and ESM Results).
Renal levels of phospho-AMPK Thr 172 and total AMPK, SIRT1, total and acetylated-Lys-PGC-1α, PPARα-ERR-1α-PGC-1α signalling, and intra-renal triacylglycerol and NEFA Western blot analysis showed that diabetes markedly decreased the phospho-AMPK Thr 172 /total AMPK ratio and the SIRT1 protein levels in db/db mice compared with db/m and db/m Res mice (Fig. 2) . Resveratrol treatment restored the phospho-AMPK Thr 172 /total AMPK, SIRT1 and total and acetylated Lys-PGC-1α levels in db/db mice to the levels of db/m and db/m Res mice ( Fig. 2a-e; p<0.01). Interestingly, the PPARα level was lower in the db/db mice compared with that in the db/m and db/m Res mice, as assessed by immunohistochemical and western blot analyses (Fig. 2f, g ). The levels of ERR-1α and SREBP1 in the kidney were evaluated to determine the changes in the PPARα target proteins. There was a decrease in ERR-1α and an increase in SREBP1 levels in db/db mice, both of which were restored with resveratrol treatment (Fig. 2g) . Consistent with the PPARα-ERR-1α-SREBP1 changes in the db/db mice, direct measurement of the intra-renal lipid concentrations showed increases in triacylglycerol and NEFA concentrations, but not in the total cholesterol concentration, in this group (Fig. 2 h-j) . Intra-renal triacylglycerol and NEFA concentrations were decreased by resveratrol treatment (p<0.05, Fig. 2i, j) .
Renal levels of PI3K, phospho-Akt Ser 473 and pFOXO3a We determined the levels of intra-renal PI3K and phospho-Akt Ser 473 using western blot analysis and PI3K activity by ELISA. The PI3K level and activity, as well as the phospho-Akt Ser 473 /total Akt ratio were significantly increased in db/db mice compared with db/m and db/m Res mice (Fig. 3a-d Fig. 3e ; p< 0.05). Treatment with resveratrol markedly decreased the level of phospho-FOXO3a Ser 253 in db/db mice, which resulted in an increase in total FOXO3a, according to the western blot analysis (Fig. 3a, f) .
Renal levels of pro-apoptotic BAX, anti-apoptotic BCL-2, cleaved caspase-3 and TUNEL-positive cells It is well known that FOXO3a activation has an anti-stress and antiapoptotic action via the enhancement of BCL-2 activity and the downregulation of pro-apoptotic BCL-2-associated X protein (BAX) activity. Consistent with the changes in FOXO3a, the BAX level on western blot was increased in samples from db/db mice compared with those from db/m and db/m Res mice (Fig. 4a) . However, the BCL-2 protein level was decreased in db/db mice compared with the db/m and db/m Res mice (Fig. 4a) . Consequently, the BAX/BCL-2 ratio was significantly increased in db/db mice, resulting in an increase in cleaved caspase-3 (Fig. 4a, c, p<0.01) , which is a critical executioner of apoptosis. In contrast, resveratrol treatment in db/db mice resulted in increased BCL-2 protein and decreased BAX protein, which resulted in a threefold increase in the ratio of BAX/BCL-2 (p<0.01) and, ultimately, a decrease in cleaved caspase-3 (Fig. 4a, c) . (Fig. 4d) .
Effects of resveratrol on SOD1, SOD2, and renal and 24 h urinary 8-OH-dG and isoprostane concentrations We investigated the changes in SOD1 and SOD2 content associated with FOXO3a activation. SOD1 and SOD2 levels were lower in db/db mice than in db/m and db/m Res mice (Fig. 5a-c) . In contrast, SOD1 and SOD2 levels were significantly increased in db/db Res mice compared with db/db mice. Increases in the renal oxidative DNA damage and lipid peroxidation, as reflected by the renal and urinary 8-OH-dG and urinary 8-isoprostane concentrations, respectively, were observed in db/db mice and were compared with the levels in db/m and db/m Res mice (Fig. 5e-f) . However, 12 weeks of resveratrol treatment decreased not only the renal 8-OH-dG level and the urinary 8-OH-dG concentration, but also the urinary 8-isoprostane concentration in db/db mice. Taken together, these findings suggest that oxidative stress in the db/db mice could be ameliorated by resveratrol treatment.
In vitro studies In diabetic db/db mice, mesangial matrix expansion, with an increased number of apoptotic mesangial cells, is one of the characteristic phenotypes of oxidative stress. As resveratrol reversed the diabetes-induced detrimental renal effects in db/db mice, we evaluated the effects of several doses of resveratrol on high-glucose-induced oxidative stress, and the effects of apoptosis related to AMPK-SIRT1-PGC-1α signalling and its downstream effector, the (Fig. 6a) and the levels of PPARα-ERR-1α (Fig. 6b) . Consistent with the change in PPARα-ERR-1α, high glucose increased the level of the lipogenic enzyme SREBP1 and decreased the lipolytic enzyme CPT-1A (Fig. 6b) . High glucose additionally increased PI3K-Akt phosphorylation and subsequent FOXO3a phosphorylation (Fig. 6b) , which related to decreases in SOD1 and LG LG +1
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LG SOD2 content, and an increase in the number of apoptotic mesangial cells (Fig. 6c, d ). In contrast, resveratrol, 1-50 ng/ ml, prevented high-glucose-induced oxidative stress and apoptosis related to the activation of AMPK-SIRT1-PGC-1α signalling and the PPARα-ERR-1α pathway. When compared with high glucose, the addition of resveratrol in low glucose did not affect the intracellular signalling and mesangial cell apoptosis. Mannitol was without any effect on the intracellular signalling (data not shown). To validate the proapoptotic effect of resveratrol as AMPK dependent, we performed additional experiments using the AMPK activators AICAR and metformin, and siRNAs for Ampkα1, Ampkα2 and Sirt1 in cultured mesangial cells. Similar to resveratrol, AICAR and metformin also activated AMPK-SIRT1-PGC-1α signalling in high-glucose conditions (Fig. 7a) . In contrast, transfection with Ampkα1, Ampkα2 and Sirt1 siRNAs suppressed resveratrol-induced AMPK-SIRT1-PGC-1α signalling, respectively, compared with resveratrol treatment only in high-glucose media (Fig. 7b, c) . Moreover, transfection with Ampkα1, Ampkα2, Sirt1 and Pgc-1α (also known as Ppargc1a) siRNAs prevented the resveratrol-induced antiapoptotic effect in mesangial cells in high-glucose media (Fig. 7d) .
Discussion
Pharmacologically targeting transcriptional networks to regulate or modulate the gene-expression programmes that favour energy expenditure is an attractive concept to combat metabolic diseases, particularly the complications of diabetes. Both AMPK and SIRT1 have emerged as interesting targets as they are heavily involved in catabolic metabolism, mitochondrial activation, angiogenesis and enhanced cell survival [3] [4] [5] [6] . It is well known that the effects of resveratrol are mediated by both SIRT1 and AMPK [24] . However, the effects of resveratrol in the kidneys of an animal model of type 2 diabetes are not well known. The results of the present study demonstrate that diabetic nephropathy in db/db mice is associated with increases in renal lipid accumulation, apoptotic renal cell injury and oxidative stress that relate to the inactivation of AMPK-SIRT1-PGC-1α signalling and the deregulation of their target molecules, PPARα-ERR-1α and PI3K-Akt-FOXO3a. Diabetic nephropathy was ameliorated by resveratrol treatment via the activation of AMPK-SIRT1-PGC-1α signalling and the subsequent activation of PPARα-ERR-1α and FOXO3a, which reversed renal lipid accumulation, apoptotic renal cell injury and oxidative stress.
It is notable that AMPK and SIRT1 regulated each other and share many common target molecules, such as PGC-1α, PPARs, FOXOs, and NF-κB. Moreover, AMPK and SIRT1 have clinical relevance with regard to metabolic syndrome and type 2 diabetes, as their effects on target molecules lead to insulin resistance, mitochondrial dysfunction, oxidative and endoplasmic reticulum stress, and lipotoxicity associated with ectopic lipid accumulation [12] . SIRT1 also responds to changes in the availability of nutrients, such as in conditions of energy-intake restriction or starvation, and energy expenditure, through a forkhead-dependent pathway [25] and PGC-1α [9] . Thus, it has been suggested that the activation of AMPK and SIRT1 allows for the concurrent deacetylation and phosphorylation of their target molecules and decreases the susceptibility to diabetes-associated disorders. The current study demonstrates that the activation of AMPK and SIRT1 by resveratrol may prevent renal lipid accumulation and cell injury related to the activation of PGC-1α. This in vitro study demonstrated that the high-glucose-induced suppression of AMPK-SIRT1-PGC-1α signalling was activated by AMPK activators, such as resveratrol, AICAR and metformin. Additionally, increased AMPK-SIRT1-PGC-1α production mediated by resveratrol in high-glucose media was suppressed with the introduction of Ampkα1, Ampkα2 and Sirt1 siRNAs. When any of one of AMPK, SIRT1 and PGC-1α was knocked down in mesangial cells, levels of the others were also reduced. These results suggest that AMPK and SIRT1 activate each other and jointly regulate the downstream PGC-1α in the mesangial cells, as in the skeletal muscles [11, 26] . Consistent with our results, several recent studies have demonstrated that AMPK activation by adiponectin [27] or AICAR [28] protected renal podocytes and diminished albuminuria in diabetic animals by decreasing NADPH oxidase 4 (NOX4)-dependent oxidative stress and apoptosis. However, Kitada et al demonstrated that resveratrol protects against diabetic nephropathy through the direct scavenging of ROS, normalisation of the Mn-SOD function and glucose-lipid metabolism via AMPK/ SIRT1-independent mechanisms [29] . The discrepancy between our results and previous studies regarding AMPK/ SIRT1 signalling might reflect differences in the dose of resveratrol administered (0.3% vs 20 mgkg
), the part of the renal tissue examined (whole kidney vs renal cortex) and the renal cell type studied (proximal epithelial cell vs mesangial cell).
PGC-1α exerts a wide array of effects and it directly coactivates multiple transcription factors, including nuclear receptors such as the PPARs [30, 31] , glucocorticoid receptors [24] , oestrogen receptors and ERRs [32, 33] , and nonnuclear receptor transcription factors, such as myocyte enhancer factor-2 [34] and the family of FOXO transcription factors [35] . By simultaneously co-activating these transcription factors, PGC-1α can quickly and coordinately modulate a transcriptional programme that governs the energy metabolism. Although PGC-1α co-activation can change in response to different stimuli or in a tissue-specific manner, in the current study, PGC-1 exerted, in part, various renal effects by enhancing the production of PPARα and its target molecule ERR-1α, in addition to co-activating FOXO3a in relation to the PI3K-Akt axis.
We and others have demonstrated that PPARα activation by PPARα agonist prevents and improves diabetes-or highfat-diet-induced renal injury by increasing the production of lipolytic enzymes and reducing lipid accumulation, oxidative stress and renal cell apoptosis, while inhibiting the development of albuminuria and glomerular fibrosis [12, 13, 36] . ERR-1α activation by PGC-1α and PPARα induces genes with roles in lipid transport [36] , oxidative phosphorylation [17, 37] , fatty acid oxidation [38, 39] , the tricarboxylic acid cycle [30, 34, 35] , mitochondrial biogenesis [17, 39] and oxidative stress defence [18] . In the current study, resveratrol increased PPARα-ERR-1α production and decreased SREBP1, and this was closely associated with decreased lipid content in the kidney. We also showed that high-glucose treatment of mesangial cells inhibits the expression of genes involved in lipolysis, such as those encoding PPARα and CPT-1A. Additionally, lipogenic genes, such as that encoding SREBP1, were induced by high-glucose treatment. Resveratrol treatment in the presence of high glucose reversed these changes, suggesting that the renoprotective impact of resveratrol may be mediated by shifting the gene-expression profile of the cells to a state that favours lipolysis.
The db/db mouse, which lacks signalling through the leptin receptor, is an excellent model of type 2 diabetes because it develops hyperphagia, obesity, hyperleptinaemia and overt hyperglycaemia [40] . In this study, db/db mice, with or without resveratrol treatment, ate about twice the amount eaten by the db/m mice. Leptin increases glucose uptake and type 1 collagen in db/db mesangial cells through a TGF-β-PI3K-dependent pathway [41] . In addition, transgenic mice with leptin overexpression demonstrated an increase in collagen type IV and fibronectin mRNA in the kidney [42] . Recently, it has been demonstrated that the reduced AMPK and SIRT1 function in db/db mice causes dysregulation of adipogenic, lipogenic and lipo-oxidative genes, including leptin, to favour an obese phenotype [42] . These results suggest that resveratrol treatment might partially improve leptin-related TGF-β-PI3K and lipid dysregulation through the activation of AMPK-SIRT1-PGC-1α in the db/db mouse kidney.
In the current study, we found that resveratrol treatment increased the production of AMPK and SIRT1 and decreased PI3K-Akt signalling in the kidneys of db/db mice and the mesangial cells in high-glucose media. In contrast, Schenk et al demonstrated that restriction of energy intake induced SIRT1 activation in mice, resulting in enhanced skeletal muscle insulin sensitivity, via PI3K modulation, and suggested that insulin-stimulated PI3K signalling is essential for the functional improvement of glucose transport in the skeletal muscle, and that SIRT1 is a key orchestrator of adaptation mediated by restriction of energy intake [43] . The discrepancy in effects in this study and the previous energy-restriction study might be because of differences in plasma insulin concentration and target organ. Restriction of energy intake augments insulin-stimulated PI3K activity in response to a physiological insulin concentration (60 μU/ml) [29] . In contrast, at the supraphysiological concentration of insulin, such as in db/db (more than 200 μU/ml) mice, PI3K would be activated in the kidney [44] .
Regarding FOXO signalling in diabetic nephropathy, a novel mechanism of diabetic nephropathy has been suggested [39] . Diabetic conditions increase TGF-β abundance in the mesangial cells and TGF-β activates p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases (ERKs), PI3K-Akt and Smads [45] . Among these, PI3K-Akt activation by TGF-β induces FOXO3a phosphorylation that results in decreased BCL-2 interacting mediator of cell death (BIM) and Mn-SOD. In contrast, another study has demonstrated that the PI3K-Akt pathway acts as a survival and antiapoptotic signal in the renal cells [46] . Overall, the data from the present study indicate that diabetes increases PI3K-Akt phosphorylation and FOXO3a phosphorylation, and this is accompanied by significant changes in the expression of key FOXO3a target genes, as reflected by the decreases in antiapoptotic BCL-2 and the antioxidants SOD1 and SOD2, and the increase in the expression of the pro-apoptotic gene Bax. Consequently, FOXO3a inactivation resulted in apoptotic renal cell death and oxidative stress. However, it is interesting that 12 weeks of treatment with resveratrol led to a protective increase in FOXO3a in the kidney, where it contributed to protection against apoptotic cell death and oxidative stress.
In conclusion, our results demonstrate that activation of AMPK and SIRT1 was associated with PCG-1α-ameliorated lipotoxicity in the kidney, which could be related to apoptosis and oxidative stress in diabetic nephropathy. Resveratrol, as an activator of AMPK-SIRT1-PGC-1α signalling, affected at least two pathways in the development of diabetic nephropathy. One pathway enhanced the PPARα-ERR-1α-SREBP1-mediated removal of lipids that had accumulated in the kidney. The other pathway decreased apoptotic renal cell death and oxidative stress related to FOXO3a activation. These signalling events may improve glomerular matrix accumulation, inflammation and albuminuria. Our data further substantiate the suggestion that high-glucose-induced mesangial cell damage translates into lower AMPK-SIRT1-PGC-1α activity and exacerbated oxidative stress and apoptotic cell damage in the setting of diabetes. All of the changes in AMPK-SIRT1-PGC-1α signalling were reversed by resveratrol treatment. These results suggest that resveratrol may be a novel therapeutic agent for type 2 diabetic nephropathy.
